B
ITOS

Braidwell’s iTeos Therapeutics ITOS Stock Holding History

Braidwell’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,162,374
Closed -$15.9M – 81
2024
Q1 		$15.9M Buy
+1,162,374
New +$12.7M 0.51% 55
2023
Q1 		– Sell
-71,585
Closed -$1.4M – 87
2022
Q4 		$1.4M Buy
+71,585
New +$1.4M 0.05% 88

Other funds holding ITOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Braidwell's ITOS Position: Q2 2024 in Review

Braidwell sold out of iTeos Therapeutics (ITOS) in Q2 2024, closing a stake of 1,162,374 shares — an estimated $15.9M sold.

Braidwell first reported a position in ITOS in Q4 2022 and held it in 2 quarters. The position peaked at $15.9M in Q1 2024. 138 funds tracked by Wall St. Rank hold ITOS as of Q2 2024.

  • Braidwell reported no remaining iTeos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Braidwell sold 1,162,374 iTeos Therapeutics shares in Q2 2024, an estimated $15.9M.
  • Braidwell first reported a position in iTeos Therapeutics in Q4 2022 and held it in 2 quarters.
  • Braidwell's iTeos Therapeutics position peaked at $15.9M in Q1 2024.
  • 138 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2024.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.